Arcus Biosciences files preliminary prospectus for common stock offering; size and price not yet set

Filed October 21, 2026 · ~1 min read

Key Changes

• high

  Offering size and price are not yet determined; last reported sale price was $23.75 per share on October 20, 2026.

  The Offering verify on EDGAR →
• medium

  Net proceeds are intended for R&D, including expansion of the casdatifan clinical program, and general corporate purposes.

  Use of Proceeds verify on EDGAR →
• high

  Investors will experience immediate dilution; 127.0 million shares outstanding as of June 30, 2026, plus 17.4 million options and 4.3 million RSUs.

  Dilution verify on EDGAR →